4D Molecular Therapeutics FDMT Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's operating lease liabilities (total)?
- 4D Molecular Therapeutics (FDMT) reported operating lease liabilities (total) of $20.54M in Q1 2026.
- How has 4D Molecular Therapeutics's operating lease liabilities (total) changed year-over-year?
- 4D Molecular Therapeutics's operating lease liabilities (total) decreased by 13.9% year-over-year, from $23.85M to $20.54M.
- What is the long-term trend for 4D Molecular Therapeutics's operating lease liabilities (total)?
- Over 4 years (2021 to 2025), 4D Molecular Therapeutics's operating lease liabilities (total) has grown at a 6.8% compound annual growth rate (CAGR), from $16.45M to $21.41M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.